Premium
Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography
Author(s) -
Gilman Sid,
Koeppe Robert A.,
Junck Larry,
Kluin Karen J.,
Lohman Mary,
St. Laurent Roy T.
Publication year - 1995
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410380209
Subject(s) - olivopontocerebellar atrophy , atrophy , cerebellum , brainstem , thalamus , basal ganglia , neuroscience , psychology , medicine , central nervous system , degenerative disease , central nervous system disease
We used positron emission tomography with [ 11 C]flumazenil to study gamma‐aminobutyric acid type A/benzodiazepine receptor binding quantitatively in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem of 72 subjects, including 14 with multiple system atrophy of the ataxic (olivopontocerebellar atrophy) type, 5 with multiple system atrophy of the extrapyramidal/autonomic (Shy‐Drager syndrome) type, 18 with sporadic olivoponto‐cerebellar atrophy, 15 with dominantly inherited olivopontocerebellar atrophy, and 20 normal control subjects with similar age and sex distributions. In comparison with data obtained from the normal control subjects, we found significantly Decemberreased ligand influx in the cerebellum and brainstem of multiple system atrophy patients of the olivopontocerebellar atrophy type and in patients with sporadic olivopontocerebellar atrophy, but not in patients with multiple system atrophy of the Shy‐Drager syndrome type. Despite these differences in ligand influx, benzodiazepine binding was largely preserved in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem in patients with multiple system atrophy of both types as well as those with sporadic or dominantly inhierited olivoponto‐cerebellar atrophy as compared with normal control subjects. The finding of relative preservation of benzodiazepine receptors indicates that these sites are available for pharmacological therapy in these disorders.